Dr. Marshall is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3800 Reservoir Rd NW
Washington, DC 20007Phone+1 202-444-2223Fax+1 202-444-1229
Summary
- Dr. Marshall received his training at Duke University, the University of Louisville, and Georgetown University. Dr. Marshall is an internationally recognized expert in new drug development for GI cancer, with expertise in phase I, II, and III trial design, and has served as Principal Investigator for more than one hundred clinical trials throughout his career. While he has an interest in many areas of cancer research, his primary focus is on the use of precision medicine in treating cancer. Dr. Marshall has become an outspoken advocate for GI cancer patients and the importance of clinical research participation. In 2009, he established the Otto J Ruesch Center for the Cure of GI Cancers, an organization solely focused on improving the lives of GI cancer patients through innovative research, personalized medicine, and focused advocacy. In 2015, Dr. Marshall both established and directed the Precision Oncology Alliance, a national alliance established to study the impact of molecular profiling on cancer research, value and outcomes. He currently is serving as the Oncology CMO for Indivumed, creating a global precision medicine research network.
Education & Training
- Georgetown University HospitalFellowship, Medical Oncology, 1991 - 1993
- MedStar Health/Georgetown-Washington Hospital CenterFellowship, Hematology and Medical Oncology, 1993
- University of Louisville School of MedicineClass of 1988
Certifications & Licensure
- VA State Medical License 1989 - 2026
- MD State Medical License 1995 - 2025
- DC State Medical License 1992 - 2024
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2013
- Super Doctor SuperDoctors.com
Clinical Trials
- Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer Start of enrollment: 2006 Jul 01
- A Study of FOLFOX6 With Bevacizumab for Biliary System Carcinoma Start of enrollment: 2009 Jun 01
- A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint Start of enrollment: 2008 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 45 citationsGlutamate metabolism in the frog retinaAnthony J. Kennedy, Mary J. Voaden, John Marshall
Nature. 1974-11-01 - 62 citationsThe integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy.Claire Reader, Sabari Vallath, Colin W. Steele, Syed Haider, Adam R. Brentnall
The Journal of Pathology. 2019-07-01 - 166 citationsIntegrins as Therapeutic Targets: Successes and CancersSabine Raab-Westphal, John Marshall, Simon L. Goodman
Cancers. 2017-08-23
Journal Articles
- Five-Fraction Stereotactic Body Radiation Therapy (SBRT) and Chemotherapy for the Local Management of Metastatic Pancreatic CancerJohn Marshall, Sean Collins, Keith Unger, Aidan Burke, Marie Gurka, Michael Pishvaian, Journal of Gastrointestinal Cancer
Press Mentions
- Oncology Unscripted with John Marshall, MD: Are You Overdosing Your Patients? Revisiting Dosing PracticesNovember 14th, 2024
- Oncology Unscripted with John Marshall: The Role of EMRs and Burnout in Physician PracticesSeptember 26th, 2024
- KRAS Inhibitors in Pancreatic Cancer: Hope on the Horizon?September 9th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: